We are live on ! Find out more
II

Ishara Investments Portfolio holdings

AUM $136M
This Fund
S&P 500
This Quarter Est. Return
+20.83%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$136M
AUM Growth
+$30.5M
Cap. Flow
+$13.3M
Cap. Flow %
9.77%
Top 10 Hldgs %
50.98%
Holding
53
New
16
Increased
13
Reduced
8
Closed
12

Top Buys

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$6.31M
2
INSM icon
Insmed
INSM
+$6.21M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$5.33M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$4.97M
5
TNXP icon
Tonix Pharmaceuticals
TNXP
+$4.36M

Top Sells

Rank Stock Value
1
KALV
KalVista Pharmaceuticals
KALV
+$5.57M
2
FOLD
Amicus Therapeutics
FOLD
+$5.34M
3
AXSM icon
Axsome Therapeutics
AXSM
+$5.33M
4
VSTM icon
Verastem
VSTM
+$4.35M
5
ARWR icon
Arrowhead Research
ARWR
+$3.47M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NKTR icon
26
Nektar Therapeutics
NKTR
$2.55B
$1.86M 1.37%
+26,650
New +$1.95M
SRRK icon
27
Scholar Rock
SRRK
$7.48B
$1.69M 1.24%
30,750
-26,650
-46% -$1.29M
ELVN icon
28
Enliven Therapeutics
ELVN
$4.5B
$1.66M 1.22%
+32,800
New +$1.39M
ALNY icon
29
Alnylam Pharmaceuticals
ALNY
$32.3B
$1.54M 1.13%
5,125
– –
BEAM icon
30
Beam Therapeutics
BEAM
$3.09B
$1.41M 1.03%
41,000
-16,400
-29% -$495K
SION
31
Sionna Therapeutics
SION
$279M
$1.35M 0.99%
123,000
+73,800
+150% +$2.95M
ORIC icon
32
Oric Pharmaceuticals
ORIC
$1.43B
$1.33M 0.98%
123,000
+20,500
+20% +$186K
NAMS icon
33
NewAmsterdam Pharma
NAMS
$3.29B
$1.25M 0.92%
36,900
– –
VRTX icon
34
Vertex Pharmaceuticals
VRTX
$139B
$1.22M 0.9%
+2,460
New +$1.09M
SPRY icon
35
ARS Pharmaceuticals
SPRY
$593M
$1.15M 0.84%
+143,490
New +$1.23M
MNPR icon
36
Monopar Therapeutics
MNPR
$758M
$1.14M 0.84%
+12,300
New +$761K
ERAS icon
37
Erasca
ERAS
$6.69B
$751K 0.55%
+41,000
New +$586K
VERA icon
38
Vera Therapeutics
VERA
$2.65B
$440K 0.32%
10,250
-71,750
-88% -$2.67M
IMTX icon
39
Immatics
IMTX
$1.29B
$311K 0.23%
30,750
-123,000
-80% -$1.3M
MREO
40
Mereo BioPharma
MREO
$44.5M
$244K 0.18%
+768,750
New +$231K
GOSS icon
41
Gossamer Bio
GOSS
$89.1M
$135K 0.1%
820,000
– –
ARDX icon
42
Ardelyx
ARDX
$1B
– –
-451,000
Closed -$2.7M
ARWR icon
43
Arrowhead Research
ARWR
$12.7B
– –
-55,350
Closed -$3.47M
CPRX
44
DELISTED
Catalyst Pharmaceutical
CPRX
– –
-82,000
Closed -$2.03M
EWTX icon
45
Edgewise Therapeutics
EWTX
$4.82B
– –
-49,200
Closed -$1.55M
FOLD
46
DELISTED
Amicus Therapeutics
FOLD
– –
-369,000
Closed -$5.34M
IDYA icon
47
IDEAYA Biosciences
IDYA
$4.07B
– –
-24,600
Closed -$820K
KALV
48
DELISTED
KalVista Pharmaceuticals
KALV
– –
-276,750
Closed -$5.57M
LGND icon
49
Ligand Pharmaceuticals
LGND
$5.77B
– –
-8,200
Closed -$1.64M
MLTX icon
50
MoonLake Immunotherapeutics
MLTX
$1.33B
– –
-174,250
Closed -$3.25M
1
2
3

Similar funds

SB
Semitam Bonam Goshen, New York $136M AUM 13.42% 1-Year Est. Return
WFA
WJ Financial Advisors Killingworth, Connecticut $136M AUM 23.45% 1-Year Est. Return
RC
Rahlfs Capital Lake Kiowa, Texas $136M AUM 33.89% 1-Year Est. Return
GBFP
Golden Bell Financial Planning Alpharetta, Georgia $136M AUM 12.99% 1-Year Est. Return
RIA
Rhodes Investment Advisors Fort Worth, Texas $136M AUM
RCWM
Red Crane Wealth Management San Francisco, California $136M AUM 18.56% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $136M AUM
HMS
Hanseatic Management Services Albuquerque, New Mexico $136M AUM

Ishara Investments's Q2 2026 Portfolio in Review

As of Q2 2026, Ishara Investments held 53 positions worth $136M, up 29% from $106M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Ishara Investments deployed $13.3M of net new capital in Q2 2026, opening 16 new positions and adding to 13 existing holdings. Its largest new stake was Insmed: 51,250 shares worth $5.46M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 94% a quarter earlier.

On the sell side, the largest reduction was Axsome Therapeutics, an estimated $5.33M trimmed.

  • Ishara Investments's largest Q2 2026 buy was Insmed: 51,250 shares worth $5.46M.
  • Ishara Investments added most to Acadia Pharmaceuticals in Q2 2026, an estimated $6.31M increase.
  • Ishara Investments's biggest Q2 2026 reduction was Axsome Therapeutics, cutting an estimated $5.33M.
  • Ishara Investments fully exited KalVista Pharmaceuticals in Q2 2026, selling an estimated $5.57M.
  • Ishara Investments's ten largest holdings make up 51% of its $136M portfolio in Q2 2026.
  • Ishara Investments opened 16 new positions and closed 12 in Q2 2026.
  • Ishara Investments's portfolio value rose 29% quarter-over-quarter to $136M.

Based on Ishara Investments's 13F filing for Q2 2026, filed 14 Aug 2026.